Rifaximin Contraindications
Rifaximin is contraindicated only in patients with hypersensitivity to rifaximin, any rifamycin antimicrobial agent, or any component of the formulation 1.
Absolute Contraindication
The sole absolute contraindication is hypersensitivity reactions, which have included:
- Exfoliative dermatitis
- Angioneurotic edema (angioedema)
- Anaphylaxis 1
This is the only FDA-labeled contraindication and represents a clear safety concern that precludes rifaximin use.
Important Clinical Limitations and Warnings (Not Contraindications)
While not absolute contraindications, the following situations require careful consideration or avoidance:
Situations Where Rifaximin Should NOT Be Used:
- Diarrhea complicated by fever or bloody stools - rifaximin is ineffective and alternative antibiotics are needed 1
- Invasive diarrheal pathogens including:
- Campylobacter jejuni (proven ineffective)
- Shigella species (effectiveness not proven)
- Salmonella species (effectiveness not proven) 1
Situations Requiring Extreme Caution:
Severe hepatic impairment (Child-Pugh Class C) - while not contraindicated, there is significantly increased systemic absorption. Clinical trials were limited to MELD scores <25, with only 8.6% having MELD >19. Exercise caution in this population 1
Concomitant P-glycoprotein inhibitors (e.g., cyclosporine) - can substantially increase systemic rifaximin exposure, particularly dangerous when combined with hepatic impairment 1
Common Pitfalls to Avoid:
- Do not confuse limitations with contraindications - fever/bloody diarrhea means rifaximin won't work, not that it's dangerous
- Cross-resistance with rifampin - rifaximin use can lead to rifampin-resistant staphylococci 2 and high-level resistant E. coli 3, which may compromise future rifampin therapy for serious infections
- Risk of C. difficile infection - like all antibiotics, rifaximin can cause CDAD, though this is a class effect, not a contraindication 1
Bottom line: The only true contraindication is hypersensitivity to rifaximin or other rifamycins. Everything else represents clinical situations where the drug either won't work or requires careful risk-benefit assessment.